Loading...
•
Dec 31, 2021
Adicet Bio Q4 2021 Earnings Report
Adicet Bio reported financial results and operational highlights.
Key Takeaways
Adicet Bio announced positive interim clinical data from Phase 1 study ADI-001 and successfully raised $94.2 million in net proceeds through a public follow-on offering. Net loss for the quarter was $15.8 million.
Announced positive interim clinical data from Phase 1 study ADI-001, with complete and near complete responses observed starting at the lowest dose level.
Successfully raised $94.2 million in net proceeds through a public follow-on offering.
Regeneron Pharmaceuticals to license the exclusive, worldwide rights to ADI-002.
ADI-001 preclinical data published in Clinical and Translational Immunology.
Forward Guidance
Adicet expects that current cash and cash equivalents and marketable debt securities as of December 31, 2021, will be sufficient to fund its operating expenses at least into the second half of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...